Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio que compara el apósito de presión negativa frente al convencional en pacientes con STB resecado tras radioterapia (TPN-RAD)

10 de noviembre de 2026 actualizado por: Centre Leon Berard

Estudio aleatorizado que compara apósitos de presión negativa versus apósitos convencionales en pacientes con sarcoma de tejido blando (STB) de extremidades o tronco resecado después de radioterapia externa

This is a randomized (1:1 ratio), prospective, comparative, controlled, open-label study. The aim is to compare the efficacy of negative pressure therapy (PREVENA™) versus standard postoperative wound management on the wound healing after surgery for previously irradiated Soft Tissue Sarcoma (STS)

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

The gold standard treatment for primary non-metastatic STS is complete surgical resection. Peri-operative Radiation Therapy (RT) has been proved to improve local control . Nevertheless, the timing of RT, whether preoperative or postoperative, remains a debate.

Both have similar local control efficacy, but preoperative RT results in lower rates of long-term fibrosis and lymphedema and improved joint mobility than postoperative RT. On the other hand, the adverse effect of pre-operative RT is a higher rate of wound post-operative complications and re-operations.

Any effort to reduce the high rate of postoperative complications could offer the advantage of preoperative RT in terms of reduced long-term sequelae compared with postoperative RT without a higher wound complication rate postoperatively. Short retrospective series of Negative Pressure Wound Therapy (NPWT) after surgical resection of Soft Tissue Sarcoma (STS) have reported very encouraging results in preventing wound complications: patients treated with NPWT were less likely to develop wound complications than those who did not receive it. Both groups did not report an increased rate of local recurrence. The use of NPWT would also reduce the cost of care by avoiding complications.

That's why the investigators propose this study comparing the use of a negative pressure dressing to a conventional dressing in patients with STS of the limbs or trunk resected after neo-adjuvant external radiotherapy.

Tipo de estudio

Intervencionista

Inscripción (Actual)

173

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Angers, Francia, 49055
        • Institut de Cancérologie de l'Ouest - Pays de Loire
      • Bordeaux, Francia, 33076
        • Institut Bergonié
      • Chambray-lès-Tours, Francia, 37170
        • CHRU Tours Hôpital Trousseau
      • Clermont-Ferrand, Francia, 63011
        • Centre Jean Perrin
      • Dijon, Francia, 21000
        • Centre Georges François Leclerc
      • Lille, Francia, 59000
        • Centre Oscar Lambert
      • Limoges, Francia, 87042
        • CHU Limoges
      • Montpellier, Francia, 34090
        • Institut du Cancer de Montpellier
      • Paris, Francia, 75014
        • APHP Hôpital Cochin
      • Rennes, Francia, 35033
        • CHU Rennes
      • Toulouse, Francia, 31100
        • IUCT Oncopole
      • Vandœuvre-lès-Nancy, Francia, 54519
        • Institut de Cancérologie de Lorraine
    • Pays de Loire
      • Nantes, Pays de Loire, Francia, 44093
        • CHU Nantes
    • Rhône-Alpes Auvergne
      • Lyon, Rhône-Alpes Auvergne, Francia, 69008
        • Centre Leon Berard

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age ≥ 18 years at the day of consenting to the study
  • Patients with primary STS of the limb or trunk treated with preoperative external radiation therapy (decided in multidisciplinary board)
  • Intent to cure resection required for STS planned between 3 to 8 weeks after the end of RT
  • Planned primary wound closure, including local or distant jambeau
  • Ability to understand and willingness for follow-up visits
  • Covered by a medical insurance
  • Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment.

Exclusion Criteria:

  • Known hypersensibility to silver
  • Patients with a diagnosis of Ewing's sarcoma, chondrosarcoma, osteosarcoma, or desmoid tumor. Nota bene: Only patients with bone tumors are affected; patients with soft tissue tumors can be included in the study.
  • Patient in relapse setting;
  • Patient requiring a surgical revision after R1 or R2 resection;
  • Planned blade drainage;
  • Planned no wound-closure and skin graft after resection
  • Patient requiring authorship or curators or patient deprived of liberty.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm A : Surgery for STS and prevena

The surgery for the STS lesion will be performed according to standard practices.

PREVENA™ Incision Management System should be applied immediately post-surgery to clean surgically closed wounds. It should be continuously applied for a minimum of 2 days and up to a maximum of 7 days (as per PREVENA user manual)

PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.

Sin intervención: Arm B : Surgery for STS and standard postoperative wound management

The surgery for the STS lesion will be performed according to standard practices.

The dressing and drainage of the wound will be performed according to usual practices, with the exception of negative pressure dressings.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The efficacy of negative pressure therapy (PREVENA) versus standard postoperative wound management on the wound healing after surgery for previously irradiated STS
Periodo de tiempo: Within the 3-month postoperative period.

Assessed by major wound complications rate

Within the 3-month postoperative period.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Three month deep infection rate
Periodo de tiempo: At 3 months post-surgery visit

Assessed by the proportion of patients experiencing a second surgery for wound healing problem within 3 postoperative months

At 3 months post-surgery visit
Three months secondary surgery for wound healing problem rate
Periodo de tiempo: At 3 months post-surgery visit

Assessed by the proportion of patients experiencing a second surgery for wound healing problem within 3 postoperative months

At 3 months post-surgery visit
Hospitalization duration
Periodo de tiempo: At 3 months post-surgery visit

Defined as the number of hospitalization days from the date of surgery to the date of discharge

At 3 months post-surgery visit
Time to complete wound healing
Periodo de tiempo: Up to 27 months

Defined as the interval from surgery to 100% healing (total wound closure with no need for dressing and any local care)

Up to 27 months
Number and types of major wound complications (MWCs)
Periodo de tiempo: Up to 27 months

Assessed by a number and differens types of a major wound complications

Up to 27 months
Quality of life using EQ-5D-5L
Periodo de tiempo: At 28 days and 3 months after surgery for each patients

Assessed by EQ-5D-5L introduce by EuroQol Group in 2009 with five dimensions : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels : no problems, slight problems, moderate problems, severe problems and extreme problems. A minimum value is 0 and a maximum value is 100. A mean worst value is 0 and a better mean value is 100.

At 28 days and 3 months after surgery for each patients
Incidence of Adverse Events
Periodo de tiempo: Up to 27months

Defined by the number of patients with Adverse Events (any type and any grade using the NCI-CTC AE scale version 5.0)

Up to 27months
Quality of life using FACT-G
Periodo de tiempo: At 28 days and 3 months after surgery for each patients

Assessed by FACT-G : Functionnal Assesment of Cancer Therapy with 27 items. There are four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being. A minimum value is 0 and a maximum value is 4. A mean worst value is 0 and a better mean value is 108.

At 28 days and 3 months after surgery for each patients

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: François Gouin, MD, Chirurgien, Centre Leon Berard

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de agosto de 2023

Finalización primaria (Actual)

7 de octubre de 2026

Finalización del estudio (Actual)

7 de octubre de 2026

Fechas de registro del estudio

Enviado por primera vez

26 de junio de 2023

Primero enviado que cumplió con los criterios de control de calidad

12 de julio de 2023

Publicado por primera vez (Actual)

13 de julio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ET22-146

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .